for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ADMA Biologics Inc

ADMA.OQ

Latest Trade

4.32USD

Change

0.00(0.00%)

Volume

301,709

Today's Range

4.21

 - 

4.59

52 Week Range

2.08

 - 

6.31

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Adma Biologics Reports Q3 Loss Per Share Of $0.19

Nov 6 (Reuters) - ADMA Biologics Inc <ADMA.O>::ADMA BIOLOGICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS.Q3 LOSS PER SHARE $0.19.Q3 REVENUE ROSE 71 PERCENT TO $7.2 MILLION.Q3 REVENUE ESTIMATE $5.5 MILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $-0.23 -- REFINITIV IBES DATA.AT SEPTEMBER 30, 2019, CO HAD CASH AND CASH EQUIVALENTS OF $48.0 MILLION AND ACCOUNTS RECEIVABLE OF $7.3 MILLION.

Adma Biologics Files For Mixed Shelf Of Upto $200 Mln - SEC Filing

Oct 4 (Reuters) - ADMA Biologics Inc <ADMA.O>::ADMA BIOLOGICS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.

ADMA Biologics Q2 Loss Per Share $0.25

Aug 8 (Reuters) - ADMA Biologics Inc <ADMA.O>::ADMA BIOLOGICS REPORTS SECOND QUARTER AND FIRST HALF 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.25.Q2 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.Q2 REVENUE ROSE 41 PERCENT TO $6.6 MILLION.Q2 REVENUE ESTIMATE $3.3 MILLION -- REFINITIV IBES DATA.COMMERCIAL LAUNCHES AND SALES OF BIVIGAM® AND ASCENIV™ IN SECOND HALF OF 2019.WE EXPECT TO GENERATE ADDITIONAL REVENUE UNDER BPC CONTRACT DURING SECOND HALF OF 2019.

Adma Biologics Receives FDA Approval For License Transfers For Bivigam And Nabi-Hb

July 8 (Reuters) - ADMA Biologics Inc <ADMA.O>::ADMA BIOLOGICS RECEIVES FDA APPROVAL FOR LICENSE TRANSFERS FOR BIVIGAM AND NABI-HB.ADMA BIOLOGICS - FDA NOTIFIED LICENSES FOR BIVIGAM & NABI-HB REVOKED FROM BIOTEST PHARMACEUTICALS & TRANSFERRED, ISSUED TO CO'S U.S. LICENSE NO. 2019.

Adma Biologics Prices Public Offering Of Common Stock At $4.00 Per Share

May 17 (Reuters) - ADMA Biologics Inc <ADMA.O>::ADMA BIOLOGICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.3 MILLION COMMON SHARES PRICED AT $4.00PER SHARE.

Adma Biologics Announces Proposed $45 Million Public Offering Of Common Stock

May 15 (Reuters) - ADMA Biologics Inc <ADMA.O>::ADMA BIOLOGICS ANNOUNCES PROPOSED $45 MILLION PUBLIC OFFERING OF COMMON STOCK.ADMA BIOLOGICS - TO USE NET PROCEEDS TO SUPPORT COMMERCIAL LAUNCH OF ASCENIV ANTICIPATED DURING H2, FOR COMMERCIAL RELAUNCH OF BIVIGAM, AMONG OTHERS.

ADMA Biologics Reports Q1 Loss Per Share $0.28

May 8 (Reuters) - ADMA Biologics Inc <ADMA.O>::ADMA BIOLOGICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.28.Q1 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.Q1 REVENUE $3.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.2 MILLION.

Adma Biologics Elects To Draw-Down $27.5 Mln In Capital From Existing Perceptive Advisors Credit Agreement

May 3 (Reuters) - ADMA Biologics Inc <ADMA.O>::ADMA BIOLOGICS ELECTS TO DRAW-DOWN $27.5 MILLION IN CAPITAL FROM EXISTING PERCEPTIVE ADVISORS CREDIT AGREEMENT.ADMA BIOLOGICS INC - ELECTED TO DRAW-DOWN $27.5 MILLION FROM ITS EXISTING CREDIT AGREEMENT WITH PERCEPTIVE ADVISORS.ADMA BIOLOGICS - CO, PERCEPTIVE ADVISORS ENTERED AMENDMENT, PROVIDING FOR AN UPSIZED, FUNDING TRANCHE COMMITMENT UPON GETTING FDA APPROVAL OF BIVGAM.ADMA BIOLOGICS INC - ADDITIONAL $12.5 MILLION COMMITMENT WILL BE AVAILABLE TO ADMA AT ITS SOLE OPTION FOLLOWING FDA APPROVAL UNTIL MARCH 31, 2020.

ADMA Biologics Gets Patent for Treatment, Prevention of Pneumococcal Infections

April 17 (Reuters) - ADMA Biologics Inc <ADMA.O>::ADMA BIOLOGICS GRANTED U.S. PATENT FOR TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTIONS.ADMA BIOLOGICS INC - TERM OF PATENT EXTENDS TO MARCH 2037..

ADMA Biologics Receives Department Of Health And Human Services U.S. License

April 2 (Reuters) - ADMA Biologics Inc <ADMA.O>::ADMA RECEIVES DEPARTMENT OF HEALTH AND HUMAN SERVICES U.S. LICENSE.ADMA BIOLOGICS INC - LICENSE AUTHORIZES ADMA TO MANUFACTURE AND ENTER INTO INTERSTATE COMMERCE WITH ASCENIV.ADMA BIOLOGICS INC - LICENSE COVERS BOCA RATON, FL MANUFACTURING FACILITY WHICH HAS DEMONSTRATED COMPLIANCE WITH FDA REQUIREMENTS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up